PHG

PHG

USD

Koninklijke Philips N.V. NY Registry Shares

$28.020-0.180 (-0.638%)

即時價格

Healthcare
醫療器材
荷蘭

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$28.200

最高

$28.525

最低

$27.830

交易量

1.00M

公司基本面

市值

26.9B

行業

醫療器材

國家

Netherlands

交易統計

平均交易量

0.74M

交易所

NYQ

貨幣

USD

52週範圍

最低 $21.48當前 $28.020最高 $29.29

相關新聞

GlobeNewswire

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA

查看更多
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
BusinessWire

Philips Joins the Forever Promise Project to Honor American Veterans

Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced its support of the Forever Promise Project, an initiative of the Monuments Men and Women Foundation that connects American

查看更多
Philips Joins the Forever Promise Project to Honor American Veterans
GlobeNewswire

Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA

October 30, 2025 10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport

查看更多
Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA
GlobeNewswire

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major

查看更多
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients